VYGR 241220 2.50C (VYGR241220C2500) Stock Options, News & Quotes

0.00
0.000.00%

15min DelayTrading Nov 27 09:30 ET

0.00High0.00Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Tonyco

Nov 17 09:43

$Voyager Therapeutics (VYGR.US)$
Very oversold, less than 1% profitable positions, undervalued by all except p/e which is still under market avg.

BeeDeeVee712

Oct 4 15:47

$Voyager Therapeutics (VYGR.US)$ I got in on this around April of this year for around $6.30-6.40 and have been holding it just waiting for it to completely crash. I'm not sure exactly what caused the uptick today but I do know I'm extremely tempted to sell it all off and take the smaller profits (actually I'm definitely going to sell some for that), but I'm not sure, I think this company still has potential long-term, I was just blown away by how stagnant it had been for months. Anyone else have...

Tonyco

Sep 19 12:29

$Voyager Therapeutics (VYGR.US)$
This was over $10 recently, and earnings were great, except Wall St was scared of recession at the time. I'm guessing once they are satisfied, this will go back up

Trytosaveabit

Sep 5 07:04

News

$Voyager Therapeutics (VYGR.US)$ Press Release: Voyager Enters Into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
Dow Jones· 2 mins ago
Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
Voyager to receive upfront consideration of $15 million and is eligible to receive up to $305 million in potential associated milestone payments and royalties

Jaguar8

Sep 5 07:01

NEWS

$Voyager Therapeutics (VYGR.US)$
Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
Voyager Therapeutics (Nasdaq: VYGR) has announced a new license agreement with Novartis AG (NYSE: NVS) for a novel capsid from Voyager's TRACER™ capsid discovery platform. The capsid will be used in a gene therapy program targeting an undisclosed rare neurologic disease. This agreement expands Voyager's partnered portfolio of TRACER-enabl...